• 1
    Longstreth GF. Epidemiology of hospitalization for acute upper gastrointestinal hemorrhage: a population-based study. Am J Gastroenterol 1995; 90(2): 20610.
  • 2
    Andrews C, Zandieh I, Brodie M, et al. Appropriateness of discontinuation of intravenous proton pump inhibitor (IV PPI) in bleeding peptic ulcer patients without high risk ulcer stigmata at endoscopy: preliminary results of multicenter evaluation. Gastrointest Endosc 2002; 55(5): AB592(Abstract) .
  • 3
    Collins R, Langman M. Treatment with histamine H2 antagonists in acute upper gastrointestinal hemorrhage. Implications of randomized trials. N Engl J Med 1985; 313(11): 6606.
  • 4
    Walt RP, Cottrell J, Mann SG, Freemantle NP, Langman MJ. Continuous intravenous famotidine for haemorrhage from peptic ulcer. Lancet 1992; 340(8827): 105862.
  • 5
    Zandieh I, Andrews C, Brodie M, et al. Prescribing practices and indications for the use of intravenous proton pump inhibitors (IV PPI) in six urban tertiary care centres. Gastrointest Endosc 2002; 55(5): T1883(Abstract) .
  • 6
    Andrews C, Zandieh I, Levy AR, et al. Comparison of intravenous proton pump inhibitor (IV PPI) use between hospitals: preliminary results. Gastrointest Endosc 2002; 55(5): T1874(Abstract) .
  • 7
    Cook DJ, Guyatt GH, Salena BJ, Laine LA. Endoscopic therapy for acute nonvariceal upper gastrointestinal hemorrhage: a meta-analysis. Gastroenterology 1992; 102(1): 13948.
  • 8
    Laine L. Multipolar electrocoagulation versus injection therapy in the treatment of bleeding peptic ulcers. A prospective, randomized trial. Gastroenterology 1990; 99(5): 13036.
  • 9
    Laine L, Peterson WL. Bleeding peptic ulcer. N Engl J Med 1994; 331(11): 71727.
  • 10
    Laine L, Estrada R. Randomized trial of normal saline solution injection versus bipolar electrocoagulation for treatment of patients with high-risk bleeding ulcers: is local tamponade enough? Gastrointest Endosc 2002; 55(1): 610.
  • 11
    Sacks HS, Chalmers TC, Blum AL, Berrier J, Pagano D. Endoscopic hemostasis. An effective therapy for bleeding peptic ulcers. J Am Med Assoc 1990; 264(4): 4949.
  • 12
    Salas M, Ward A, Caro J. Are proton pump inhibitors the first choice for acute treatment of gastric ulcers? A meta analysis of randomized clinical trials. BMC Gastroenterol 2002; 2(1): 17.
  • 13
    Scott LJ, Dunn CJ, Mallarkey G, Sharpe M. Esomeprazole: a review of its use in the management of acid-related disorders. Drugs 2002; 62(10): 150338.
  • 14
    Conrad SA. Acute upper gastrointestinal bleeding in critically ill patients: causes and treatment modalities. Crit Care Med 2002; 30(6 Suppl.): S3658.
  • 15
    Laine L. Esomeprazole in the treatment of Helicobacter pylori. Aliment Pharmacol Ther 2002; 16(Suppl. 4): 1158.
  • 16
    Tytgat GN. Treatment of mild and severe cases of GERD. Aliment Pharmacol Ther 2002; 16(Suppl. 4): 738.
  • 17
    Erstad BL. Proton-pump inhibitors for acute peptic ulcer bleeding. Ann Pharmacother 2001; 35(6): 73040.
  • 18
    Yacyshyn BR, Thomson AB. Critical review of acid suppression in nonvariceal, acute, upper gastrointestinal bleeding. Dig Dis 2000; 18(3): 11728.
  • 19
    Daneshmend TK, Hawkey CJ, Langman MJ, Logan RF, Long RG, Walt RP. Omeprazole versus placebo for acute upper gastrointestinal bleeding: randomised double blind controlled trial. Br Med J 1992; 304(6820): 1437.
  • 20
    Lau JY, Sung JJ, Lee KK, et al. Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. N Engl J Med 2000; 343(5): 3106.
  • 21
    Brunner GH, Thiesemann C. The potential clinical role of intravenous omeprazole. Digestion 1992; 51(Suppl. 1): 1720.
  • 22
    Hasselgren G, Lind T, Lundell L, et al. Continuous intravenous infusion of omeprazole in elderly patients with peptic ulcer bleeding. Results of a placebo-controlled multicenter study. Scand J Gastroenterol 1997; 32(4): 32833.
  • 23
    Lin HJ, Lo WC, Lee FY, Perng CL, Tseng GY. A prospective randomized comparative trial showing that omeprazole prevents rebleeding in patients with bleeding peptic ulcer after successful endoscopic therapy. Arch Intern Med 1998; 158(1): 548.
  • 24
    Schaffalitzky de Muckadell OB, Havelund T, Harling H, et al. Effect of omeprazole on the outcome of endoscopically treated bleeding peptic ulcers. Randomized double-blind placebo-controlled multicentre study. Scand J Gastroenterol 1997; 32(4): 3207.
  • 25
    Zed PJ, Loewen PS, Slavik RS, Marra CA. Meta-analysis of proton pump inhibitors in treatment of bleeding peptic ulcers. Ann Pharmacother 2001; 35(12): 152834.
  • 26
    Barkun AN, Chiba N, Enns RA, et al. Use of a national endoscopic database to determine the adoption of emerging pharmacological and endoscopic technologies in the every day care of patients with upper GI bleeding. The RUGBE initiative. Am J Gastroenterol 2000; 96(9): S261(AB833)(Abstract).
  • 27
    Barkun AN, Cockeram AW, Plourde V, Fedorak RN. Review article: acid suppression in non-variceal acute upper gastrointestinal bleeding. Aliment Pharmacol Ther 1999; 13(12): 156584.
  • 28
    Katschinski B, Logan R, Davies J, Faulkner G, Pearson J, Langman M. Prognostic factors in upper gastrointestinal bleeding. Dig Dis Sci 1994; 39(4): 70612.
  • 29
    Levine JE, Leontiadis GI, Sharma VK, Howden CW. Meta-analysis: the efficacy of intravenous H2-receptor antagonists in bleeding peptic ulcer. Aliment Pharmacol Ther 2002; 16(6): 113742.
  • 30
    Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. Oxford: Oxford University Press, 1997.
  • 31
    Phelps CE, Mushlin AI. Focusing technology assessment using medical decision theory. Med Decis Making 1988; 8(4): 27989.
  • 32
    Canadian Institute for Health Information. DAD: Discharge Abstract Database. Ottawa: Canadian Institute for Health Information, 2000.
  • 33
    Institute of Health Economics. A National List of Provincial Costs for Health Care: Canada, 1997/8. Edmonton: Institute of Health Economics, 2000.
  • 34
    British Columbia Ministry of Health Services. Medical Services Commission Payment Schedule. Victoria: Government of British Columbia Ministry of Health Services, 2001.
  • 35
    IMS Health. Retail Pharmacy Dispensed Prescription Costs: Canada and Provinces, 1999. Pointe-Claire: IMS Health, 2000.
  • 36
    Manning WG, Fryback DG, Weinstein MC. Reflecting uncertainty in cost-effectiveness analysis. In: GoldMR, SiegelJE, RussellLB, WeinsteinMC, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996: 24775.
  • 37
    Briggs AH, Gray AM. Handling uncertainty when performing economic evaluation of healthcare interventions. Health Technol Assess 1999; 3(2): 1134.
  • 38
    Briggs AH, Gray AM. Handling uncertainty in economic evaluations of healthcare interventions. Br Med J 1999; 319(7210): 6358.
  • 39
    Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000; 17(5): 479500.
  • 40
    Critchfield GC, Willard KE, Connelly DP. Probabilistic sensitivity analysis methods for general decision models. Comput Biomed Res 1986; 19(3): 25465.
  • 41
    Critchfield GC, Willard KE. Probabilistic analysis of decision trees using Monte Carlo simulation. Med Decis Making 1986; 6(2): 8592.
  • 42
    Doubilet P, Begg CB, Weinstein MC, Braun P, McNeil BJ. Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach. Med Decis Making 1985; 5(2): 15777.
  • 43
    Spiegel BM, Vakil NB, Ofman JJ. Endoscopy for acute nonvariceal upper gastrointestinal tract hemorrhage: is sooner better? A systematic review. Arch Intern Med 2001; 161(11): 1393404.
  • 44
    Cooper GS, Chak A, Way LE, Hammar PJ, Harper DL, Rosenthal GE. Early endoscopy in upper gastrointestinal hemorrhage: associations with recurrent bleeding, surgery, and length of hospital stay. Gastrointest Endosc 1999; 49(2): 14552.
  • 45
    Van Hout BA, Al MJ, Gordon GS, Rutten FF. Costs, effects and C/E-ratios alongside a clinical trial. Health Econ 1994; 3(5): 30919.
  • 46
    Briggs AH. Handling uncertainty in economic evaluation and presenting results. In: DrummondM, McGuireA, eds. Economic Evaluation in Health Care: Merging Theory with Practice. New York: Oxford University Press, 2001: 172214.
  • 47
    Briggs AH, O'Brien BJ, Blackhouse G. Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies. Annu Rev Public Health 2002; 23: 377401.
  • 48
    Briggs A, Fenn P. Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. Health Econ 1998; 7(8): 72340.
  • 49
    Kleinman L, McIntosh E, Ryan M, et al. Willingness to pay for complete symptom relief of gastroesophageal reflux disease. Arch Intern Med 2002; 162(12): 13616.
  • 50
    Eastaugh SR. Willingness to pay in treatment of bleeding disorders. Int J Technol Assess Health Care 2000; 16(2): 70610.
  • 51
    Redelmeier DA, Fuchs VR. Hospital expenditures in the United States and Canada. N Engl J Med 1993; 328(11): 7728.
  • 52
    Fuchs VR, Hahn JS. How does Canada do it? A comparison of expenditures for physicians' services in the United States and Canada. N Engl J Med 1990; 323(13): 88490.